Discover the Future of Cross-Linking
Our device will fit on all major slit lamp models and can be mounted within seconds.
The C-Eye device will constantly measure the amount of fluorescence that is emitted by the excited riboflavin. The amount of fluorescence correponds to the concentration of riboflavin in the cornea and the measurement is distance-dependent.
The C-Eye device constantly measures the riboflavin fluorescence. If too low levels are detected, the device will stop irradiation.
There are two possibilities for too ow levels:
- Low levels at start of treatment: the riboflavin was not administrered long enough and there is not enough riboflavin in the stroma, or the patient has moved its head away from the chinrest. Re-check the position of the patient’s head. If it was correct, then re-apply riboflavin and start the procedure.
- Low levels during the treatment: if the C-Eye device allowed the treatment to start, the concentration of riboflavin was sufficient and will stay sufficient over the few minutes needed for treatment. In this case, whenever the device stops irradiation during the treatment, the most probable reason is a major movement of the patient’s head.
The device is operated using single-use caps. They are the sterile interface between device and patient’s eye.
The irradiation emitted by the C-Eye device will be higher in the periphery of the cornea to compensate for the increased corneal thickness in the periphery.
The C-Eye device will offer different treatment intensities, all of which are scientifically validated for either CXL or PACK-CXL: 3, 9, 18 and 30 mW/cm2.
The C-Eye Device has no CE mark yet. Obtention is expected for spring 2017.
In 2015, the WHO established the “Global Review on Antimicrobial Resistance”
It states that “Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill”.
The graphic shows that by 2050, the WHO expects that more people will die due to antibiotic resistance than to cancer and diabetes combined.
For ophthalmology this will mean a distinct increase in antibiotic-resistant corneal infections.
PACK-CXL kills bacteria irrespective of their antibiotic resistance.
- PACK-CXL also kills funghi, making it potentially attractive in mixed corneal infections.